Telomir Pharmaceuticals, Inc. - Common Stock (TELO)
1.3100
-0.0400 (-2.96%)
NASDAQ · Last Trade: Nov 8th, 4:58 PM EST
Detailed Quote
Previous Close
1.350
Open
1.330
Bid
1.310
Ask
1.350
Day's Range
1.272 - 1.330
52 Week Range
1.120 - 7.079
Volume
286,556
Market Cap
42.29M
PE Ratio (TTM)
1.424
EPS (TTM)
0.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,742,432
Chart
About Telomir Pharmaceuticals, Inc. - Common Stock (TELO)
Telomir Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies that target cellular aging and age-related diseases. The company specializes in the research and development of medications aimed at enhancing telomere function, which plays a crucial role in cellular health and longevity. By leveraging advanced scientific insights, Telomir Pharmaceuticals aims to transform the treatment landscape for conditions such as cancer and degenerative diseases, ultimately striving to improve the quality of life for patients by addressing the underlying mechanisms of aging. Read More
New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer.
Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for partnerships, licensing, and long-term value creation.
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation.
Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models.
Telomir's stock jumped nearly 39% in after-hours trading following news that its lead compound, Telomir-1, showed potential in reversing cancer-related DNA changes in aggressive prostate cancer models.
New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth.
New preclinical findings highlight Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene - often called the body's natural "cell cycle brake." These results build on prior STAT1 data, supporting Telomir-1's profile as a potential first-in-class broad-spectrum DNA methylation reset therapy.
